Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15459096 | 0.89 | PDE2A (0.38) | PDE2ANOTUMHIF1A | |
| SCHEMBL190968 | 0.83 | GABRA1 (0.52) | GABRA1GABRB2NOTUMPOLBKDM4E | |
| SCHEMBL1104681 | 0.82 | NOTUM (0.47) | GABRA1GABRB2NOTUMPOLBMAPT | |
| SCHEMBL28241863 | 0.81 | GABRA1 (0.50) | GABRA1GABRB2NOTUMPOLBKDM4E | |
| SCHEMBL20379861 | 0.81 | PDE2A (0.33) | PDE2ANOTUM | |
| SCHEMBL16261286 | 0.80 | GABRA1 (0.41) | GABRA1GABRB2PDE2APOLBKDM4E | |
| SCHEMBL13095523 | 0.79 | GABRA1 (0.41) | GABRA1GABRB2NOTUM | |
| SCHEMBL17716413 | 0.79 | GABRA1 (0.41) | GABRA1GABRB2NOTUMCYP1A2CYP2D6 | |
| SCHEMBL15459372 | 0.79 | PDE2A (0.32) | PDE2ANOTUM | |
| SCHEMBL846677 | 0.78 | GABRA1 (0.46) | GABRA1GABRB2NOTUMPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | GABRA1 341/4885GABRB2 476/4885PDE2A 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.